Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...

This decision delays Sun Pharma's planned US launch of the product, which could be deferred for several months if the company ...

Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming that the drug infringed a US patent (No. 9,662,335) ...

Sun Pharma faces a delay in the U.S. launch of its drug Leqselvi due to a preliminary injunction by the New Jersey court, ...

According to Citi, the delay in the launch of Sun Pharma's alopecia areata drug, Leqselvi, could impact its near-term ...

Leqselvi, projected to generate around $200 million in sales over the next three to four years for Sun Pharma, was slated for ...

Thirty out of the 41 analysts tracking the company have a 'buy' rating on the stock, seven suggest a 'hold' and four have a ...

Sun Pharmaceuticals Ltd. announced on Saturday that the US District Court of New Jersey has granted a preliminary injunction ...

Pharma giant, Sun Pharmaceutical's launch of its specialty drug Leqselvi in the U.S. market is in limbo as the U.S. District Court in New Jersey has issued a preliminary injunction.

Given the investments of around $576 million and the peak revenues potential upwards of $200 million, four years down the ...

Shares of Sun Pharmaceutical Industries declined five per cent to Rs 1,766.15 in early trade on the BSE on Monday following a ...